Clinical trialNCT07030907RecruitingPhase 1Interventional

A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer

SponsorOutpace Bio, Inc.Enrollment30Ovarian CancerOvarian Cancer RecurrentPlatinum Resistant Ovarian Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The goal of this clinical trial is to learn if OPB-101 is safe in platinum resistant ovarian cancer participants and also to find the optimal dose of OPB-101. Participants will have their own T cells modified in a laboratory and given back to them as OPB-101 in this one-time treatment. Participants will be in the hospital when they receive OPB-101 and then be checked at the clinical site frequently for the first few months.

clinicaltrials.gov ↗

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Karmanos Cancer Institute
Detroit, Michigan, United States
Recruiting
University of Minnesota
Minneapolis, Minnesota, United States
Melissa Geller, MD
Recruiting
Roswell Park
Buffalo, New York, United States
Emese Zsiros, MD
Recruiting
Md Anderson Cancer Center
Houston, Texas, United States
Amir Jazaeri, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

OPB-101

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 16 Jun 2025
Primary completion: 15 May 2028
Completion: 15 May 2030
Last update posted: 18 Dec 2025
Registered enrollment: 30
Registry id: NCT07030907

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.